miR-345在非小细胞肺癌中的表达及临床意义

doi:10.11904/j.issn.1002-3070.2017.02.005

Abstract

Abstract: Objective The objective of this study was to investigate the miR-345 expression level in non-small cell lung cancer(NSCLC)tissue and its potential clinical significance.Methods Real-time PCR was conducted to evaluate the expression of miR-345 in NSCLC tissues in 98 samples and cell lines.Then the association between tissue miR-345 expression level and clinical outcomes was further analyzed.Results The expression level of miR-345 was significantly decreased in NSCLC tissues and cell lines when compared to the controls(P＜0.05).miR-345 expression level in NSCLS tissues was associated with various clinicopathological parameters including LN metastasis(P＜0.001),distant metastasis(P=0.028),TNM stage(P=0.004)and grade(P=0.011).In addition,the NSCLC patients in the low miR-345 expression group showed significantly shorter overall survival time than that in the high miR-345expression group(P=0.021).Multivariate analysis showed that the expression of miR-345 was an independent risk factor for NSCLC(HR=3.897,95% CI:2.263~10.440;P=0.012).Conclusion The expression level of miR-345 was decreased in NSCLC tissues as well as cell lines compared with normal controls.Low miR-345 expression in tissues was associated with progression and poor prognosis of NSCLC.These results indicate that miR-345 may be a novel prognostic marker in NSCLC.

Key words: Biomarker, miR-345, Non-small cell lung cancer, Prognosis

CLC Number:

R734.2

HU Haifeng,FENG Xiemin,QIAO Jian,DUAN Wei,LIU Ningning,SUN Xiaodong. The expression and clinical significance of miR-345 in non-small cell lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 117-122.

References

1 Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].CA Cancer J Clin,2016,6(1):7-30.
2 Wink KC,Roelofs E,Solberg T,et al.Particle therapy for non-small cell lung tumors:where do we stand? A systematic review of the literature[J].Front Oncol,2014,4(32):292-296.
3 Blevins R,Bruno L,Carroll T,et al.MicroRNAs regulate cell-to-cell variability of endogenous target gene expression in developing mouse thymocytes[J].PLoS Genet,2015,11(2):e1005020.
4 Inamura K,Ishikawa Y.MicroRNA in lung cancer:novel biomarkers and potential tools for treatment[J].J Clin Med,2016,5(3):36-39.
5 高大登,李华栋,禹亮,等.MicroRNA与非小细胞肺癌关系的研究进展[J].现代生物医学研究进展,2013,13(14):2797-2800.
6 Nadal E,Truini A,Nakata A,et al.A novel serum 4-microRNA signature for lung cancer detection[J].Sci Rep,2015,5(1):12464-12468.
7 Mavridis K,Gueugnon F,Petit-Courty A,et al.The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients[J].Br J Cancer,2015,112(9):1527-1535.
8 Wang SY,Shiboski S,Belair CD,et al.MiR-19,miR-345,miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance[J].PLoS One,2014,9(6):e98597.
9 Kaur S,Lotsari JE,Al-Sohaily S,et al.Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma[J].Clinical Epigenetics,2015,7(1):1-13.
10 Xue LM,Dong L,Yong ZM,et al.Overexpression of miR-708 and its targets in the childhood common precursor B-cell ALL[J].Pediatr Blood Cancer,2013,60(12):2060-2067.
11 Chen PS,Su JL,Hung MC.Dysregulation of microRNAs in cancer[J].Febs Letters,2012,19(1):1-8.
12 Ruan K,Fang X,Ouyang G.MicroRNAs:novel regulators in the hallmarks of human cancer[J].Cancer Lett,2009,285(2):116-126.
13 Pichler M,Calin GA.MicroRNAs in cancer:from developmental genes in worms to their clinical application in patients[J].Br J Cancer,2015,113(4):569-573.
14 Xue W,Dahlman JE,Tammela T,et al.Small RNA combination therapy for lung cancer[J].Proc Natl Acad Sci U S A,2014,111(34):3553-3561.
15 Sun Z,Yu JT,Jiang T,et al.Genome-wide microRNA profiling of rat hippocampus after status epilepticus induced by amygdala stimulation identifies modulators of neuronal apoptosis[J].PLoS One,2013,8(10):e78375.
16 Martinez-Ramos R,Garcia-Lozano JR,Lucena JM,et al.Differential expression pattern of microRNAs in CD4⁺ and CD19⁺ cells from asymptomatic patients with systemic lupus erythematosus[J].Lupus,2014,23(4):353-359.
17 Chen QG,Zhou W,Han T,et al.MiR-345 suppresses proliferation,migration and invasion by targeting Smad1 in human prostate cancer[J].J Cancer Res Clin Oncol,2016,142(1):213-224.
18 Srivastava SK,Bhardwaj A,Arora S,et al.MicroRNA-345 induces apoptosis in pancreatic cancer cells through potentiation of caspase-dependent and-independent pathways[J].Br J Cancer,2015,113(4):660-668.
19 Tang JT,Wang JL,Du W,et al.MicroRNA 345,a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer[J].Carcinogenesis,2011,32(8):1207-1215.
20 Schou JV,Rossi S,Jensen BV,et al.MiR-345 in metastatic colorectal cancer:a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan[J].PLoS One,2014,9(6):e99886.
21 Brito JA,Gomes CC,Guimaraes AL,et al.Relationship between microRNA expression levels and histopathological features of dysplasia in oral leukoplakia[J].J Oral Pathol Med,2014,43(3):211-216.
22 Gayosso-Gomez LV,Zarraga-Granados G,Paredes-Garcia P,et al.Identification of circulating miRNAs profiles that distinguish malignant pleural mesothelioma from lung adenocarcinoma[J].Excli J,2014,13(3):740-750.

[1]	ZHANG Jiawen,YU Yan,ZHANG Wei,CAO Jingyan,LUO Wen,SHANG Lihua. Serum metabolomics of small cell lung cancer patients based on UPLC-TOF/MS [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 200-205.
[2]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[3]	FENG Yue,XING Linan,WANG Zhao,ZHANG Yunyan. Correlation between NLR and prognosis of concurrent chemoradiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 284-288.
[4]	BAI Xiaobin, HUO Longwei, XIE Wanfu, XU Gaofeng, WANG Maode. Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 122-127.
[5]	SHI Xiaokang, DING Youming, WANG Bin, YU Bin, XU Yu. Expression and clinical significance of UBE2T in primary liver cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 128-133.
[6]	LU Jiaoyun, ZHANG Qingyuan. Advances in laboratory markers in the prognosis of diffuse large B-cell lymphoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 183-187.
[7]	ZHAO Fengjuan, WANG Qi, REN Yunhong, WEI Jueling, LI Lequn, ZHAO Xinhua, TANG Juan, YOU Xuemei. Changes of serum CRP and hs-CRP levels in patients with liver cancer and depression and their influence on prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 27-33.
[8]	ZHANG Fengchun, JIANG Ying, LIU Zhaonan, YAN Ningning, CUI Hongquan, XU Yingchun. Prognostic significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in systemic inflammation-related indicators in gastric cancer patients after radical resection [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 34-39.
[9]	MA Jianli, ZHANG Minghui, JI Hongfei, XU Xiangying. Clinical significance of combined detection of PD-L1 protein and CD8⁺TILs in resected lung adenocarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 40-46.
[10]	YANG Hongbo, SHI Jie, YE Yong, LI Wencheng, DENG Zhaoping. Expression of COL5A2 in bladder cancer tissues and its correlation with clinicopathological features and prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 52-56.
[11]	WANG Yalong, LYU Zhangyan, ZHANG Fan, FENG Xiaoshuang, WEI Luopei, LI Xin, WEN Yan, GAO Yushun, XUE Qi, GAO Shugeng, TAN Fengwei. Relationship between human papillomavirus infection and prognosis of lung cancer:A meta-analysis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 520-526.
[12]	TANG Shuli, HE Kuangbang, ZHANG Chunhui, CHENG Jianan, ZHANG Yanqiao. Expression of miR-320a and CYLD in gastric cancer and its relationship with clinicopathological characteristics and prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 538-544.
[13]	XIAO Hongwei, CHEN Sheng, WANG Yanliang, SU Xueliang. The prognostic and influence factors analysis of transanal local resection for stage T₁ rectal cancer with the distance from anal margin ≤8 cm [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 545-549.
[14]	LI Wanzhen, YIN Jun, LI Ping, LIN Xiaohui, ZHANG Guoqian, ZHANG Shuxu. The expression and role of miR-17 in radioresistant cells of non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 391-397.
[15]	WANG Yiran, HUANG Wei, YIN Lei, LIU Lin, ZHOU Xiaoping, NIU Xingjian, YANG Yue, AN Weiwei, JI Hongfei. The ratio of neutrophil to lymphocyte in the efficacy and prognosis of concurrent chemoradiotherapy in patients with cervical cancer and its clinical significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 404-409.

The expression and clinical significance of miR-345 in non-small cell lung cancer

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments